孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用对小儿呼吸道感染后咳嗽的疗效评价

目的 探讨小儿呼吸道感染后咳嗽患儿实施孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用治疗的疗效评价。方法 选择我院2018年1月～2019年12月收治的300例小儿呼吸道感染后咳嗽患儿作为研究对象,并分为观察组(150例,实施孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用治疗方式)和对照组(150例,实施口服孟鲁司特治疗方式),对两组小儿呼吸道感染后咳嗽患儿经治疗后的症状消失时间、治疗效果、不良反应发生率进行比较。结果 观察组呼吸困难消失时间为(3.34±1.23)d、气喘消失时间为(3.45±1.45)d、哮鸣音消失时间为(5.37±1.67)d、咳嗽消失时间为(5.43±2.11)d,均短于对照组,差异有统计学意义(P0.05);观察组治疗总有效率为90.00%,明显高于对照组的82.00%,差异有统计学意义(P0.05);观察组不良反应发生率为19.33%,低于对照组的42.67%,差异有统计学意义(P0.05)。结论 对小儿呼吸道感染后咳嗽患儿实施孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用治疗,能帮助患儿缓解咳嗽症状,提升患儿的治疗效果,减少患儿不良反应的发生率,帮助患儿尽快恢复正常呼吸状态。

Efficacy evaluation of montelukast combined with budesonide and compound ipratropium bromide inhalation in treating cough after respiratory tract infection in children

Objective To explore the therapeutic effect of montelukast combined with budesonide and compound ipratropium bromide inhalation in children with cough after respiratory tract infection.Methods Three hundred children with cough after respiratory tract infection who were admitted to our hospital from January 2018 to December 2019 were selected as research objects and divided into the observation group,with 150 children treated with montelukast combined with budesonide and compound ipratropium bromide inhalation,and the control group,with 150 children treated with the oral montelukast.The symptom disappearance time,treatment effect and adverse reaction rate of children with cough after respiratory tract infection after treatment were compared between the two groups.Results The vanishing times of dyspnea,asthma,wheezing and cough in the observation group were(3.34±1.23) d,(3.45±1.45)d,(5.37±1.67)d and(5.43±2.11)d,respectively,which were shorter than those in the control group,with statistically significant differences(P<0.05).The total effective rate of treatment of the observation group was 90.00%,which was significantly highter than 82.00% of the control group,with statistically significant difference(P<0.05).The incidence of adverse reactions in the observation group was 19.33%,which was lower than 42.67% in the control group,and the difference was statistically significant(P<0.05).Conclusion The combined treatment of montelukast,budesonide and compound ipratropium bromide inhalation in children with cough after respiratory tract infection can help relieve cough symptoms,improve the treatment effect,reduce the incidence of adverse reactions in children,and help children return to normal breathing as soon as possible.